SEC Filings

Form 10-K
EXICURE, INC. filed this Form 10-K on 03/08/2019
Document Outline
Entire Document (6080.6 KB)
Subdocument 1 - 10-K - 10-K
Page 1 - UNITED STATES
Page 2 - DOCUMENTS INCORPORATED BY REFERENCE
Page 3 - EXICURE, INC.
Page 4 - CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Page 5 - N/A
Page 6 - TRADEMARKS
Page 7 - PART I
Page 8 - Inflammatory diseases
Page 9 - Other Inflammatory Diseases
Page 10 - Our Strategy
Page 11 - Introduction to Nucleic Acid Therapeutics
Page 12 - Examples of our proprietary SNA constructs
Page 13 - Immuno-oncology SNAs may produce a powerful immune response against tumors.
Page 14 - SNAs for immuno-oncology
Page 15 - Phase 1 clinical development of AST-008
Page 16 - Preclinical data for AST-008
Page 17 - AST-008 in combination with a certain anti-PD-1 antibody in breast cancer mouse model resistant to a
Page 18 - XCUR17 a topically applied anti-IL-17RA SNA
Page 19 - Phase 1 clinical development for XCUR17
Page 20 - Topical application of XCUR17 in a prototype gel to healthy human skin ex vivo results in a dose-dep
Page 21 - Neurology
Page 22 - Gastroenterology
Page 23 - Dermelix License Agreement
Page 24 - Trade Secret and Other Protection
Page 25 - in vitro
Page 26 - Manufacturing and Supply
Page 27 - Competition
Page 28 - Government Regulation and Product Approval
Page 29 - in vitro
Page 30 - N/A
Page 31 - Companion Diagnostics
Page 32 - N/A
Page 33 - N/A
Page 34 - N/A
Page 35 - New Legislation and Regulations
Page 36 - Healthcare Reform
Page 37 - Third-Party Payor Coverage and Reimbursement
Page 38 - N/A
Page 39 - Other Healthcare Laws and Regulations
Page 40 - Environment
Page 41 - Advisors
Page 42 - Available Information
Page 43 - Item 1A. Risk Factors.
Page 44 - Our therapeutic candidates are in early stages of development and may fail in development or suffer
Page 45 - Product development involves a lengthy and expensive process with an uncertain outcome, and results
Page 46 - Our quarterly operating results may fluctuate significantly or may fall below the expectations of in
Page 47 - We may not successfully engage in strategic transactions, including any additional collaborations we
Page 48 - Because we rely on third party manufacturing and supply partners, our supply of research and develop
Page 49 - We face competition from entities that have developed or may develop therapeutic candidates for our
Page 50 - The market may not be receptive to our therapeutic candidates based on a novel therapeutic modality,
Page 51 - Any inability to attract and retain qualified key management and technical personnel would impair ou
Page 52 - Price controls imposed in foreign markets may adversely affect our future profitability.
Page 53 - Our employees may engage in misconduct or other improper activities, including noncompliance with re
Page 54 - We are subject to European data protection laws, including the new EU General Data Protection Regula
Page 55 - Our current operations are concentrated in one location and any events affecting this location may h
Page 56 - We have incurred significant losses since our inception and expect to incur continued losses in the
Page 57 - Association for Molecular Pathology v. Myriad Genetics, Inc.
Page 58 - We currently license patent rights from Northwestern University and may in the future license patent
Page 59 - inter alia
Page 60 - If we fail to comply with our obligations under any license, collaboration or other agreements, we m
Page 61 - We may be subject to claims that we or our employees or consultants have wrongfully used or disclose
Page 62 - Risks Related to Government Regulation
Page 63 - Certain of our therapeutic candidates may require companion diagnostics in certain indications. Fail
Page 64 - N/A
Page 65 - Any therapeutics we develop may become subject to unfavorable pricing regulations, third party cover
Page 66 - N/A
Page 67 - The healthcare industry is heavily regulated in the U.S. at the federal, state, and local levels, an
Page 68 - Our ability to obtain services, reimbursement or funding from the federal government may be impacted
Page 69 - Significant developments stemming from the United Kingdom s recent referendum on membership in the E
Page 70 - Our stock price may be volatile and purchasers of our common stock could incur substantial losses.
Page 71 - The future issuance of equity or of debt securities that are convertible into equity may dilute your
Page 72 - The employment agreements with our executive officers may require us to pay severance benefits to of
Page 73 - The designation of our common stock as a penny stock would limit the liquidity of our common stock.
Page 74 - Anti-takeover provisions in our charter documents and under the General Corporation Law of the State
Page 75 - Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable futur
Page 76 - Item 1B. Unresolved Staff Comments.
Page 77 - PART II
Page 78 - N/A
Page 79 - Item 6. Selected Financial Data.
Page 80 - Statement of Operations
Page 81 - Item 7. Management s Discussion and Analysis of Financial Condition and Results of Operations.
Page 82 - Inflammatory diseases
Page 83 - Other Inflammatory Diseases
Page 84 - Basis of Presentation
Page 85 - Recent Developments
Page 86 - Trading of Common Stock
Page 87 - Identify the performance obligations in the contract.
Page 88 - Licenses of intellectual property
Page 89 - Common stock warrant liability
Page 90 - Research and development expense
Page 91 - General and administrative expense
Page 92 - Results of Operations
Page 93 - Research and development expense
Page 94 - Interest expense
Page 95 - Operating activities
Page 96 - Subsequent Events
Page 97 - Contractual Obligations and Commitments
Page 98 - JOBS Act
Page 99 - Item 8. Financial Statements and Supplementary Data.
Page 100 - Report of Independent Registered Public Accounting Firm
Page 101 - EXICURE, INC.
Page 102 - EXICURE, INC.
Page 103 - EXICURE, INC.
Page 104 - EXICURE, INC.
Page 105 - EXICURE, INC.
Page 106 - EXICURE, INC.
Page 107 - EXICURE, INC.
Page 108 - EXICURE, INC.
Page 109 - EXICURE, INC.
Page 110 - EXICURE, INC.
Page 111 - EXICURE, INC.
Page 112 - EXICURE, INC.
Page 113 - EXICURE, INC.
Page 114 - EXICURE, INC.
Page 115 - EXICURE, INC.
Page 116 - EXICURE, INC.
Page 117 - EXICURE, INC.
Page 118 - EXICURE, INC.
Page 119 - EXICURE, INC.
Page 120 - EXICURE, INC.
Page 121 - EXICURE, INC.
Page 122 - EXICURE, INC.
Page 123 - EXICURE, INC.
Page 124 - EXICURE, INC.
Page 125 - EXICURE, INC.
Page 126 - EXICURE, INC.
Page 127 - EXICURE, INC.
Page 128 - Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.
Page 129 - Item 9B. Other Information.
Page 130 - PART III
Page 131 - PART IV
Page 132 - N/A
Page 133 - Item 16. Form 10-K Summary.
Page 134 - SIGNATURES
Page 135 - POWER OF ATTORNEY
Subdocument 2 - EX-10.18.2 - EXHIBIT 10.18.2
Page 1 - Exhibit 10.18.2
Page 2 - Exhibit 10.18.2
Page 3 - Exhibit 10.18.2
Page 4 - Exhibit 10.18.2
Page 5 - IN WITNESS WHEREOF,
Subdocument 3 - EX-21.1 - EXHIBIT 21.1
Page 1 - N/A
Subdocument 4 - EX-23.1 - EXHIBIT 23.1
Page 1 - N/A
Subdocument 5 - EX-31.1 - EXHIBIT 31.1
Page 1 - N/A
Subdocument 6 - EX-31.2 - EXHIBIT 31.2
Page 1 - N/A
Subdocument 7 - EX-32.1 - EXHIBIT 32.1
Page 1 - N/A
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT (What's this?)
XBRL Viewer

Print Page  | E-mail Page  | RSS Feeds  | E-mail Alerts  | IR Contacts  | Financial Tear Sheet